veligrotug   Click here for help

GtoPdb Ligand ID: 14572

Synonyms: AVE-1642 | AVE1642 | Lumvoa®: | veligrotug-vvze | VRDN-001
Approved drug Immunopharmacology Ligand
veligrotug is an approved drug
Compound class: Antibody
Comment: Veligrotug (AVE-1642) is a monoclonal antibody that targets insulin-like growth factor 1 receptor (IGF1R) [4].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Veligrotug (AVE-1642) was progressed as a clinical lead, initially for anti-tumour potential [2,8,10]. In a change of direction the antibody was further evaluated as a treatment for autoimmune thyroid eye disease (TED) [3]. The US FDA approved veligrotug as a treatment for TED in June 2026 [7].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05176639 A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) Phase 3 Interventional Viridian Therapeutics, Inc. 11
NCT06021054 An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) Phase 3 Interventional Viridian Therapeutics, Inc.
NCT06179875 An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054) Phase 3 Interventional Viridian Therapeutics, Inc.
NCT01233895 Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma Phase 1 Interventional Sanofi